Deal could earn Evotec over $7.67 million in research funding and milestones.
Vifor Pharma could pay Evotec over €5.5 million (about $7.67 million) as part of a deal centered on the search for a new preclinical candidate to treat anemia. The agreement will leverage Evotec’s integrated biology, chemistry, and preclinical development expertise. Evotec will be responsible for all discovery activities and project management, in return for research funding and success-based milestone payments.
“This agreement represents a great step forward in our business model, as we are committed to identifying a preclinical candidate within an agreed budget,” states Werner Lanthaler, Ph.D., Evotec CEO. “This will allow us to fully integrate and leverage all of our research sites and scientists to efficiently deliver a preclinical candidate to Vifor Pharma.”
Vifor Pharma is the pharmaceuticals business of the Galenica Group. The company operates in both the prescription pharmaceutical and OTC product markets. Vifor’s prescription drug unit is focused on the development of new products for anemia but is also active in the fields of kidney and autoimmune diseases.
